Autor: "Tamura, T" - OpacWWW

Skocz do pozycji: 1.

Tytuł:: First-line nivolumab, paclitaxel, carboplatin, and bevacizumab for advanced non-squamous non-small cell lung cancer: Updated survival analysis of the ONO-4538-52/TASUKI-52 randomized controlled trial.
Autorzy:: Kim HR; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
Sugawara S; Department of Pulmonary Medicine, Sendai Kousei Hospital, Miyagi, Japan.
Lee JS; Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul, National University Bundang Hospital, Gyeonggi-do, South Korea.
Kang JH; Department of Medical Oncology, The Catholic University of Korea Seoul St. Mary's Hospital, Seoul, South Korea.
Inui N; Department of Pulmonary Medicine, Hamamatsu University Hospital, Shizuoka, Japan.
Hida T; Department of Thoracic Oncology, Aichi Cancer Center, Aichi, Japan.
Lee KH; Department of Internal Medicine, Chungbuk National University Hospital, Chungcheongbuk-do, South Korea.
Yoshida T; Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Tanaka H; Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan.
Yang CT; Department of Thoracic Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan.
Nishio M; Department of Thoracic Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research (JFCR), Tokyo, Japan.
Ohe Y; Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Tamura T; Thoracic Center, St. Luke's International Hospital, Tokyo, Japan.
Yamamoto N; Internal Medicine III, Wakayama Medical University, Wakayama, Japan.
Yu CJ; Department of Internal Medicine, National Taiwan University Hospital Hsin-Chu Branch, Hsinchu County, Taipei, Taiwan.
Akamatsu H; Internal Medicine III, Wakayama Medical University, Wakayama, Japan.
Takahashi S; Oncology Clinical Development Planning 1, Ono Pharmaceutical Co., Ltd., Osaka, Japan.
Nakagawa K; Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan.; Pokaż więcej
Źródło:: Cancer medicine [Cancer Med] 2023 Aug; Vol. 12 (16), pp. 17061-17067. Date of Electronic Publication: 2023 Aug 28.
Typ publikacji:: Randomized Controlled Trial; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Carcinoma, Non-Small-Cell Lung*/drug therapy
Lung Neoplasms*/drug therapy
Humans ; Nivolumab/adverse effects ; Bevacizumab/adverse effects ; Paclitaxel/adverse effects ; Carboplatin/adverse effects ; Platinum ; Protein-Tyrosine Kinases ; Proto-Oncogene Proteins ; Neoplasm Recurrence, Local ; Survival Analysis ; ErbB Receptors ; Receptor Protein-Tyrosine Kinases

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 2.

Tytuł:: Safety of anti-SARS-CoV-2 messenger RNA vaccine in lung cancer patients undergoing anticancer chemotherapy: A multicenter, prospective, observational, patient-reported outcome study.
Autorzy:: Harada D; Department of Thoracic Oncology, NHO Shikoku Cancer Center, Matsuyama, Japan.
Tamura T; Department of Respiratory Medicine, NHO Iwakuni Clinical Center, Iwakuni, Japan.
Ninomiya K; Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Kubo T; Center for Clinical Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Kuyama S; Department of Respiratory Medicine, NHO Iwakuni Clinical Center, Iwakuni, Japan.
Tachibana S; Department of Respiratory Medicine, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Inoue K; Department of Respiratory Medicine, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Chikamori K; Department of Medical Oncology, National Hospital Organization Yamaguchi-Ube Medical Center, Ube, Japan.
Kudo K; Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Okayama, Japan.
Ochi N; General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan.
Maeda Y; Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Kiura K; Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.; Pokaż więcej
Źródło:: Thoracic cancer [Thorac Cancer] 2023 Jan; Vol. 14 (3), pp. 231-236. Date of Electronic Publication: 2022 Nov 20.
Typ publikacji:: Observational Study; Multicenter Study; Journal Article
MeSH Terms:: COVID-19*
Lung Neoplasms*
Male ; Humans ; Aged ; Female ; COVID-19 Vaccines ; BNT162 Vaccine ; Prospective Studies ; SARS-CoV-2 ; Cytotoxins ; Fever
SCR Organism:: SARS-CoV-2 variants

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 3.

Tytuł:: Short-term safety of an anti-severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine for patients with advanced lung cancer treated with anticancer drugs: A multicenter, prospective, observational study.
Autorzy:: Tamura T; Department of Respiratory Medicine, NHO Iwakuni Clinical Center, Iwakuni, Japan.
Ninomiya K; Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Kubo T; Center for Clinical Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Kuyama S; Department of Respiratory Medicine, NHO Iwakuni Clinical Center, Iwakuni, Japan.
Tachibana S; Department of Respiratory Medicine, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Inoue K; Department of Respiratory Medicine, Ehime Prefectural Central Hospital, Matsuyama, Japan.
Chikamori K; Department of Medical Oncology, National Hospital Organization Yamaguchi-Ube Medical Center, Ube, Japan.
Kudo K; Department of Respiratory Medicine, National Hospital Organization Okayama Medical Center, Okayama, Japan.
Ochi N; General Internal Medicine 4, Kawasaki Medical School, Okayama, Japan.
Harada D; Department of Thoracic Oncology, NHO Shikoku Cancer Center, Matsuyama, Japan.
Maeda Y; Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
Kiura K; Department of Allergy and Respiratory Medicine, Okayama University Hospital, Okayama, Japan.; Pokaż więcej
Źródło:: Thoracic cancer [Thorac Cancer] 2022 Feb; Vol. 13 (3), pp. 453-459. Date of Electronic Publication: 2021 Dec 28.
Typ publikacji:: Journal Article; Multicenter Study; Observational Study; Research Support, Non-U.S. Gov't
MeSH Terms:: Antineoplastic Agents*
COVID-19*
Lung Neoplasms*/drug therapy
Aged ; BNT162 Vaccine ; COVID-19 Vaccines ; Humans ; Male ; Prospective Studies ; SARS-CoV-2 ; Vaccines, Synthetic ; mRNA Vaccines

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 4.

Tytuł:: Carboplatin, pemetrexed, and pembrolizumab was effective for primary salivary gland-type lung adenocarcinoma diagnosed due to esophageal stricture: A case report.
Autorzy:: Kawakado K; Department of Respiratory Medicine, National Hospital Organization Iwakuni Clinical Center, Iawkuni-City, Japan.; Department of Internal Medicine, Division of Medical Oncology and Respiratory Medicine, Shimane University Faculty of Medicine, Izumo, Japan.
Tamura T; Department of Respiratory Medicine, National Hospital Organization Iwakuni Clinical Center, Iawkuni-City, Japan.
Nakanishi M; Department of Respiratory Medicine, National Hospital Organization Iwakuni Clinical Center, Iawkuni-City, Japan.
Makimoto G; Department of Respiratory Medicine, National Hospital Organization Iwakuni Clinical Center, Iawkuni-City, Japan.
Sato Y; Department of Pathology, National Hospital Organization Iwakuni Clinical Center, Iawkuni-City, Japan.
Kuyama S; Department of Respiratory Medicine, National Hospital Organization Iwakuni Clinical Center, Iawkuni-City, Japan.; Pokaż więcej
Źródło:: Thoracic cancer [Thorac Cancer] 2021 Sep; Vol. 12 (18), pp. 2513-2516. Date of Electronic Publication: 2021 Aug 08.
Typ publikacji:: Case Reports
MeSH Terms:: Adenocarcinoma of Lung/*drug therapy
Antibodies, Monoclonal, Humanized/*therapeutic use
Carboplatin/*therapeutic use
Lung Neoplasms/*drug therapy
Pemetrexed/*therapeutic use
Adenocarcinoma of Lung/pathology ; Aged ; Antineoplastic Agents/therapeutic use ; Antineoplastic Agents, Immunological/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Deglutition Disorders ; Esophageal Stenosis ; Fatal Outcome ; Female ; Humans ; Lung Neoplasms/pathology ; Salivary Glands/pathology

Raport

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 5.

Tytuł:: Limited effect of afatinib in a non-small cell lung cancer patient harboring an epidermal growth factor receptor K860I missense mutation: A case report.
Autorzy:: Tamura T
Kawakado K
Makimoto G
Nakanishi M
Kuyama S; Department of Respiratory Medicine, National Hospital Organization Iwakuni Clinical Center, Yamaguchi, Japan.; Pokaż więcej
Źródło:: Thoracic cancer [Thorac Cancer] 2021 Jun; Vol. 12 (11), pp. 1770-1774. Date of Electronic Publication: 2021 May 04.
Typ publikacji:: Case Reports; Journal Article
MeSH Terms:: Afatinib/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
ErbB Receptors/*metabolism
Lung Neoplasms/*drug therapy
Protein Kinase Inhibitors/*therapeutic use
Afatinib/pharmacology ; Aged ; Carcinoma, Non-Small-Cell Lung/pathology ; Female ; Humans ; Lung Neoplasms/pathology ; Mutation, Missense ; Protein Kinase Inhibitors/pharmacology

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 6.

Tytuł:: Three-year follow-up results from phase II studies of nivolumab in Japanese patients with previously treated advanced non-small cell lung cancer: Pooled analysis of ONO-4538-05 and ONO-4538-06 studies.
Autorzy:: Horinouchi H; Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
Nishio M; Department of Thoracic Medical Oncology, Cancer Institute Hospital, Tokyo, Japan.
Hida T; Department of Thoracic Oncology, Aichi Cancer Center Hospital, Nagoya, Japan.
Nakagawa K; Department of Medical Oncology, Faculty of Medicine, Kindai University, Osaka, Japan.
Sakai H; Department of Thoracic Oncology, Saitama Cancer Center, Saitama, Japan.
Nogami N; Division of Thoracic Oncology and Medicine, National Hospital Organization Shikoku Cancer Center, Ehime, Japan.
Atagi S; Department of Internal Medicine, Kinki-Chuo Chest Medical Center, Sakai, Japan.
Takahashi T; Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
Saka H; Department of Medical Oncology, Nagoya Medical Center, Nagoya, Japan.
Takenoyama M; Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Katakami N; Department of Medical Oncology, Kobe City Medical Center, Kobe, Japan.
Tanaka H; Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata, Japan.
Takeda K; Department of Medical Oncology, Osaka City General Hospital, Osaka, Japan.
Satouchi M; Department of Thoracic Oncology, Hyogo Cancer Center, Hyogo, Japan.
Isobe H; Department of Medical Oncology, KKR Sapporo Medical Center, Sapporo, Japan.
Maemondo M; Division of Pulmonary Medicine, Allergy and Rheumatology, Department of Internal Medicine, Iwate Medical University School of Medicine, Iwate, Japan.; Department of Respiratory Medicine, Miyagi Cancer Center, Miyagi, Japan.
Goto K; Division of Thoracic Oncology, National Cancer Center Hospital East, Chiba, Japan.
Hirashima T; Department of Thoracic Oncology, Osaka Habikino Medical Center, Osaka, Japan.
Minato K; Division of Respiratory Medicine, Gunma Prefectural Cancer Center, Gunma, Japan.
Sumiyoshi N; Oncology Clinical Development Planning, Ono Pharmaceutical Co., Ltd, Osaka, Japan.
Tamura T; Thoracic Center, St. Luke's International Hospital, Tokyo, Japan.; Pokaż więcej
Źródło:: Cancer medicine [Cancer Med] 2019 Sep; Vol. 8 (11), pp. 5183-5193. Date of Electronic Publication: 2019 Jul 29.
Typ publikacji:: Journal Article; Meta-Analysis
MeSH Terms:: Antineoplastic Agents, Immunological/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Carcinoma, Non-Small-Cell Lung/*pathology
Lung Neoplasms/*drug therapy
Lung Neoplasms/*pathology
Nivolumab/*therapeutic use
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Agents, Immunological/adverse effects ; Biomarkers, Tumor ; Carcinoma, Non-Small-Cell Lung/etiology ; Carcinoma, Non-Small-Cell Lung/mortality ; Clinical Trials, Phase II as Topic ; Female ; Humans ; Japan ; Kaplan-Meier Estimate ; Lung Neoplasms/etiology ; Lung Neoplasms/mortality ; Male ; Middle Aged ; Molecular Targeted Therapy ; Neoplasm Metastasis ; Neoplasm Staging ; Nivolumab/administration & dosage ; Nivolumab/adverse effects ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 7.

Tytuł:: Lung cancer in patients with combined pulmonary fibrosis and emphysema.
Autorzy:: Tamura T; Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba-Mito Kyodo General Hospital, Ibaraki, Japan.
Kagohashi K; Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba-Mito Kyodo General Hospital, Ibaraki, Japan.
Satoh H; Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba-Mito Kyodo General Hospital, Ibaraki, Japan.; Pokaż więcej
Źródło:: The clinical respiratory journal [Clin Respir J] 2018 Mar; Vol. 12 (3), pp. 1304. Date of Electronic Publication: 2017 Apr 26.
Typ publikacji:: Letter; Comment
MeSH Terms:: Emphysema*
Idiopathic Pulmonary Fibrosis*
Lung Neoplasms*
Pulmonary Emphysema*
Humans

Opinia redakcyjna

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 8.

Tytuł:: Establishment of highly metastatic KRAS mutant lung cancer cell sublines in long-term three-dimensional low attachment cultures.
Autorzy:: Nakano T; Division of General Thoracic Surgery, Jichi Medical University, Shimotsuke, Tochigi, Japan.; Division of Integrative Pathology, Jichi Medical University, Shimotsuke, Tochigi, Japan.
Kanai Y; Division of General Thoracic Surgery, Jichi Medical University, Shimotsuke, Tochigi, Japan.
Amano Y; Division of Integrative Pathology, Jichi Medical University, Shimotsuke, Tochigi, Japan.
Yoshimoto T; Division of Integrative Pathology, Jichi Medical University, Shimotsuke, Tochigi, Japan.
Matsubara D; Division of Integrative Pathology, Jichi Medical University, Shimotsuke, Tochigi, Japan.
Shibano T; Division of General Thoracic Surgery, Jichi Medical University, Shimotsuke, Tochigi, Japan.
Tamura T; Division of Integrative Pathology, Jichi Medical University, Shimotsuke, Tochigi, Japan.
Oguni S; Division of Integrative Pathology, Jichi Medical University, Shimotsuke, Tochigi, Japan.
Katashiba S; Division of Integrative Pathology, Jichi Medical University, Shimotsuke, Tochigi, Japan.
Ito T; Molecular Pathology Laboratory, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Murakami Y; Molecular Pathology Laboratory, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Fukayama M; Department of Human Pathology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Murakami T; Department of Microbiology, Faculty of Medicine, Saitama Medical University, Moroyama, Saitama, Japan.
Endo S; Division of General Thoracic Surgery, Jichi Medical University, Shimotsuke, Tochigi, Japan.
Niki T; Division of Integrative Pathology, Jichi Medical University, Shimotsuke, Tochigi, Japan.; Pokaż więcej
Źródło:: PloS one [PLoS One] 2017 Aug 07; Vol. 12 (8), pp. e0181342. Date of Electronic Publication: 2017 Aug 07 (Print Publication: 2017).
Typ publikacji:: Journal Article
MeSH Terms:: Cell Culture Techniques*/instrumentation
Cell Line, Tumor*/pathology
Cell Line, Tumor*/physiology
Neoplasm Metastasis*/genetics
Neoplasm Metastasis*/pathology
Neoplasm Metastasis*/physiopathology
Adenocarcinoma/*pathology
Lung Neoplasms/*pathology
Proto-Oncogene Proteins p21(ras)/*genetics
A549 Cells ; Adenocarcinoma/genetics ; Adenocarcinoma/physiopathology ; Adenocarcinoma/secondary ; Animals ; Apoptosis/physiology ; Cell Adhesion ; Cell Movement ; Cell Proliferation ; Female ; Genes, myc ; Humans ; Lung Neoplasms/genetics ; Lung Neoplasms/physiopathology ; Mice, Inbred NOD ; Mice, SCID ; Mutation ; Neoplasm Transplantation ; Organic Cation Transport Proteins/metabolism ; Spheroids, Cellular/pathology ; Zinc Finger E-box-Binding Homeobox 1/genetics ; Zinc Finger E-box-Binding Homeobox 1/metabolism

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 9.

Tytuł:: Cortical Actin Alteration at the Matrix-Side Cytoplasm in Lung Adenocarcinoma Cells and Its Significance in Invasion.
Autorzy:: Tomii S; Department of Pathology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.
Akashi T
Ando N
Tamura T
Sakurai A
Terada A
Furukawa A
Suzuki Y
Kayamori K
Sakamoto K
Ishibashi H
Eishi Y; Pokaż więcej
Źródło:: Pathobiology : journal of immunopathology, molecular and cellular biology [Pathobiology] 2017; Vol. 84 (4), pp. 171-183. Date of Electronic Publication: 2016 Dec 22.
Typ publikacji:: Journal Article
MeSH Terms:: Actins/*metabolism
Adenocarcinoma/*pathology
Lung Neoplasms/*pathology
A549 Cells ; Adenocarcinoma/diagnosis ; Adenocarcinoma of Lung ; Cell Membrane/metabolism ; Cell Movement ; Cytoplasm/metabolism ; Heterocyclic Compounds, 4 or More Rings/pharmacology ; Humans ; Immunohistochemistry ; Lung Neoplasms/diagnosis ; Myosins/drug effects ; Neoplasm Invasiveness ; Neoplasm Metastasis ; Prognosis

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 10.

Tytuł:: Frequent loss of the expression of multiple subunits of the SWI/SNF complex in large cell carcinoma and pleomorphic carcinoma of the lung.
Autorzy:: Yoshimoto T; Department of Integrative Pathology, Jichi Medical University, Shimotsuke, Japan.
Matsubara D; Department of Integrative Pathology, Jichi Medical University, Shimotsuke, Japan.; Molecular Pathology Laboratory, Institute of Medical Science, University of Tokyo, Tokyo, Japan.
Nakano T; Division of General Thoracic Surgery, Jichi Medical University, Shimotsuke, Japan.
Tamura T; Department of Integrative Pathology, Jichi Medical University, Shimotsuke, Japan.
Endo S; Division of General Thoracic Surgery, Jichi Medical University, Shimotsuke, Japan.
Sugiyama Y; Division of Pulmonary Medicine, Jichi Medical University, Shimotsuke, Japan.
Niki T; Department of Integrative Pathology, Jichi Medical University, Shimotsuke, Japan.; Pokaż więcej
Źródło:: Pathology international [Pathol Int] 2015 Nov; Vol. 65 (11), pp. 595-602. Date of Electronic Publication: 2015 Sep 08.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Carcinoma, Large Cell/*metabolism
Cell Nucleus/*metabolism
DNA-Binding Proteins/*metabolism
Lung Neoplasms/*metabolism
Transcription Factors/*metabolism
Aged ; Aged, 80 and over ; Carcinoma, Large Cell/pathology ; Carcinoma, Squamous Cell/metabolism ; Carcinoma, Squamous Cell/pathology ; Cell Nucleus/pathology ; Female ; Humans ; Lung Neoplasms/pathology ; Male ; Middle Aged

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 11.

Tytuł:: Successful Afatinib Therapy after Resistance to EGFR-TKI in a Patient with Advanced Adenosquamous Cell Lung Cancer.
Autorzy:: Tamura T; Division of Respiratory Medicine, Mito Medical Center, University of Tsukuba, Mito, Japan.
Kagohashi K
Satoh H; Pokaż więcej
Źródło:: Oncology research and treatment [Oncol Res Treat] 2015; Vol. 38 (6), pp. 316-7. Date of Electronic Publication: 2015 Jun 01.
Typ publikacji:: Case Reports; Letter
MeSH Terms:: Drug Resistance, Neoplasm*
Carcinoma, Adenosquamous/*drug therapy
ErbB Receptors/*antagonists & inhibitors
Lung Neoplasms/*drug therapy
Protein Kinase Inhibitors/*therapeutic use
Quinazolines/*therapeutic use
Afatinib ; Aged ; ErbB Receptors/genetics ; Female ; Humans ; Mutation

Raport

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 12.

Tytuł:: Immunohistochemical analysis of the expression of E-cadherin and ZEB1 in non-small cell lung cancer.
Autorzy:: Matsubara D; Molecular Pathology Laboratory, Institute of Medical Science, University of Tokyo, Tokyo, Japan; Department of Integrative Pathology, Jichi Medical University, Tochigi, Japan.
Kishaba Y
Yoshimoto T
Sakuma Y
Sakatani T
Tamura T
Endo S
Sugiyama Y
Murakami Y
Niki T; Pokaż więcej
Źródło:: Pathology international [Pathol Int] 2014 Nov; Vol. 64 (11), pp. 560-8. Date of Electronic Publication: 2014 Oct 27.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:: Cadherins/*metabolism
Carcinoma, Non-Small-Cell Lung/*metabolism
Epithelial-Mesenchymal Transition/*physiology
Homeodomain Proteins/*metabolism
Lung Neoplasms/*metabolism
Transcription Factors/*metabolism
Adenocarcinoma/metabolism ; Adenocarcinoma of Lung ; Adult ; Aged ; Aged, 80 and over ; Biomarkers, Tumor/metabolism ; Carcinoma, Non-Small-Cell Lung/pathology ; Cell Line, Tumor ; Female ; Humans ; Immunohistochemistry ; Lung Neoplasms/pathology ; Male ; Middle Aged ; Zinc Finger E-box-Binding Homeobox 1

Czasopismo naukowe

na półce

Pełny tekst Pełny tekst Szczegóły

Skocz do pozycji: 13.

Tytuł:: Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer.
Autorzy:: Nishio M; Department of Thoracic Medical Oncology, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-ku, Japan. />Horai T
Horiike A
Nokihara H
Yamamoto N
Takahashi T
Murakami H
Yamamoto N
Koizumi F
Nishio K
Yusa W
Koyama N
Tamura T; Pokaż więcej
Źródło:: British journal of cancer [Br J Cancer] 2013 Aug 06; Vol. 109 (3), pp. 538-44. Date of Electronic Publication: 2013 Jul 16.
Typ publikacji:: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:: Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Antineoplastic Combined Chemotherapy Protocols/*adverse effects
Carcinoma, Non-Small-Cell Lung/*drug therapy
Lung Neoplasms/*drug therapy
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics ; Carboplatin/administration & dosage ; Carboplatin/adverse effects ; Carcinoma, Non-Small-Cell Lung/blood ; Carcinoma, Non-Small-Cell Lung/metabolism ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Female ; Humans ; Lung Neoplasms/blood ; Lung Neoplasms/metabolism ; Male ; Middle Aged ; Paclitaxel/administration & dosage ; Paclitaxel/adverse effects ; Phenylurea Compounds/administration & dosage ; Phenylurea Compounds/adverse effects ; Quinolines/administration & dosage ; Quinolines/adverse effects

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 14.

Tytuł:: Radiotherapy quality assurance review in a multi-center randomized trial of limited-disease small cell lung cancer: the Japan Clinical Oncology Group (JCOG) trial 0202.
Autorzy:: Sanuki-Fujimoto N; Clinical Trials and Practice Support Division, Center for Cancer Control and Information Services, National Cancer Center, 5-1-1 Tsukiji, Chuo-ku, Tokyo, Japan. />Ishikura S
Hayakawa K
Kubota K
Nishiwaki Y
Tamura T; Pokaż więcej
Źródło:: Radiation oncology (London, England) [Radiat Oncol] 2009 Jun 02; Vol. 4, pp. 16. Date of Electronic Publication: 2009 Jun 02.
Typ publikacji:: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:: Quality Assurance, Health Care*
Lung Neoplasms/*radiotherapy
Radiotherapy/*standards
Small Cell Lung Carcinoma/*radiotherapy
Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Combined Modality Therapy ; Humans ; Japan ; Small Cell Lung Carcinoma/drug therapy

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 15.

Tytuł:: Characteristics and outcomes of patients with advanced non-small-cell lung cancer who declined to participate in randomised clinical chemotherapy trials.
Autorzy:: Tanai C; Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan. />Nokihara H
Yamamoto S
Kunitoh H
Yamamoto N
Sekine I
Ohe Y
Tamura T; Pokaż więcej
Źródło:: British journal of cancer [Br J Cancer] 2009 Apr 07; Vol. 100 (7), pp. 1037-42. Date of Electronic Publication: 2009 Mar 17.
Typ publikacji:: Journal Article
MeSH Terms:: Patient Participation*
Randomized Controlled Trials as Topic*
Carcinoma, Non-Small-Cell Lung/*drug therapy
Lung Neoplasms/*drug therapy
Adult ; Aged ; Carcinoma, Non-Small-Cell Lung/mortality ; Female ; Humans ; Lung Neoplasms/mortality ; Male ; Middle Aged ; Proportional Hazards Models ; Retrospective Studies ; Treatment Outcome

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 16.

Tytuł:: A randomised trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer (JCOG9811).
Autorzy:: Kunitoh H; Department of Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045, Japan. />Tamura T
Shibata T
Imai M
Nishiwaki Y
Nishio M
Yokoyama A
Watanabe K
Noda K
Saijo N; Pokaż więcej
Corporate Authors:: JCOG Lung Cancer Study Group, Tokyo, Japan
Źródło:: British journal of cancer [Br J Cancer] 2009 Feb 10; Vol. 100 (3), pp. 464-9. Date of Electronic Publication: 2009 Jan 20.
Typ publikacji:: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:: Antibiotics, Antineoplastic/*therapeutic use
Bleomycin/*therapeutic use
Lung Neoplasms/*drug therapy
Pericardial Effusion/*drug therapy
Adult ; Aged ; Antibiotics, Antineoplastic/administration & dosage ; Antibiotics, Antineoplastic/adverse effects ; Bleomycin/administration & dosage ; Bleomycin/adverse effects ; Female ; Humans ; Lung Neoplasms/complications ; Male ; Middle Aged ; Pericardial Effusion/complications ; Pericardium ; Survival Analysis

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 17.

Tytuł:: Randomised phase II trial of irinotecan plus cisplatin vs irinotecan, cisplatin plus etoposide repeated every 3 weeks in patients with extensive-disease small-cell lung cancer.
Autorzy:: Sekine I; Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan. />Nokihara H
Takeda K
Nishiwaki Y
Nakagawa K
Isobe H
Mori K
Matsui K
Saijo N
Tamura T; Pokaż więcej
Źródło:: British journal of cancer [Br J Cancer] 2008 Feb 26; Vol. 98 (4), pp. 693-6. Date of Electronic Publication: 2008 Feb 05.
Typ publikacji:: Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Carcinoma, Small Cell/*drug therapy
Lung Neoplasms/*drug therapy
Adult ; Aged ; Camptothecin/administration & dosage ; Camptothecin/analogs & derivatives ; Cisplatin/administration & dosage ; Etoposide/administration & dosage ; Female ; Humans ; Irinotecan ; Male ; Middle Aged ; Prospective Studies ; Survival Rate

Czasopismo naukowe

na półce

Pełny tekst Szczegóły

Skocz do pozycji: 18.

Tytuł:: Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702.
Autorzy:: Okamoto H; Department of Respiratory Medicine, Yokohama Municipal Citizen's Hospital, 56 Okazawa-cho, Hodogaya-ku, Yokohama, Kanagawa 240-8555, Japan. />Watanabe K
Kunikane H
Yokoyama A
Kudoh S
Asakawa T
Shibata T
Kunitoh H
Tamura T
Saijo N; Pokaż więcej
Źródło:: British journal of cancer [Br J Cancer] 2007 Jul 16; Vol. 97 (2), pp. 162-9. Date of Electronic Publication: 2007 Jun 19.
Typ publikacji:: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms:: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Carcinoma, Small Cell/*drug therapy
Lung Neoplasms/*drug therapy
Aged ; Carboplatin/administration & dosage ; Cisplatin/administration & dosage ; Cisplatin/therapeutic use ; Etoposide/administration & dosage ; Etoposide/therapeutic use ; Female ; Humans ; Male ; Middle Aged ; Treatment Outcome
SCR Protocol:: VP-P protocol